BMS/Celgene Post-Merger Early R&D Strategy: Partnerships Are Still Key, Vessey Says
Research and early development head Rupert Vessey, who had a similar role at Celgene, told Scrip that integration of the company’s pipeline into Bristol is nearly complete with few overlapping programs.
You may also be interested in...
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.
BIO hosts summit to support collaborations on coronavirus vaccines and therapeutics, Vir advances COVID-19 antibody candidates, Gilead renounces orphan status for remdesivir, BMS joins Pfizer in pushing back investor meeting, and ASCO goes virtual.
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…